ReviewMolecular biology reports2026
Curcumin-mediated modulation of immunogenic cancer cell death pathways.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunogenic cell death (ICD) is a regulated form of cell death characterized by the release of danger-associated molecular patterns (DAMPs) such as calreticulin, ATP, and HMGB1, which activate dendritic cells and cytotoxic T lymphocytes to promote antitumor immunity. This review focuses on the molecular mechanisms underlying DAMP release and associated signaling pathways, with an emphasis on how curcumin modulate ICD. Curcumin serves as a representative compound, exhibiting the ability to trigger ICD through endoplasmic reticulum stress, oxidative stress modulation, calcium homeostasis disruption, and ferroptosis induction. The diversity of cell death modalities elicited by curcumin reflects tumor type-specific differences in stress-response capacity, redox buffering, and metabolic vulnerabilities. Understanding these mechanisms provides a basis for developing curcumin-based strategies to enhance cancer immunotherapy efficacy.
Indexed as
Identifiers
41739293What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.